Keywords: genentech, texas, biotech, renegotiate, argatroban, deal, after

Genentech And Texas Biotech Renegotiate Argatroban Deal After Delays

Article | 03 July 1995

Print This

Genentech and Texas Biotechnology are in the process of renegotiating rights to Novastan (argatroban) after delays in the development of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in